Get the Stockscreener App
22.99
2.27%
0.51
After Hours:
22.99
Arcus Biosciences Inc stock is traded at $22.99, with a volume of 877.99K.
It is up +2.27% in the last 24 hours and down -0.43% over the past month.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
See More
Previous Close:
$22.48
Open:
$22.5
24h Volume:
877.99K
Relative Volume:
0.48
Market Cap:
$2.84B
Revenue:
$247.00M
Net Income/Loss:
$-249.00M
P/E Ratio:
-7.4401
EPS:
-3.09
Net Cash Flow:
$-267.00M
1W Performance:
+4.74%
1M Performance:
-0.43%
6M Performance:
+124.73%
1Y Performance:
+70.68%
1-Day Range:
$22.25
$23.07
1-Week Range:
$21.75
$23.78
52-Week Range:
$6.50
$26.40
Arcus Biosciences Inc Stock (RCUS) Company Profile
Name
Arcus Biosciences Inc
Sector
Industry
Phone
(510) 694-6200
Address
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
22.99 | 2.78B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-26 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-26-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-21-24 | Initiated | H.C. Wainwright | Neutral |
| Oct-08-24 | Initiated | Wells Fargo | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Nov-23-20 | Initiated | Evercore ISI | Outperform |
| Apr-03-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Sep-27-19 | Initiated | Mizuho | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Oct-09-18 | Initiated | Wedbush | Outperform |
| Apr-09-18 | Initiated | Citigroup | Buy |
| Apr-09-18 | Initiated | Goldman | Neutral |
| Apr-09-18 | Initiated | Leerink Partners | Outperform |
View All
Arcus Biosciences Inc Stock (RCUS) Latest News
Arcus Biosciences Grants Stock Options to Employees - Intellectia AI
Arcus Biosciences Announces New Employment Inducement Grants - marketscreener.com
New Arcus Biosciences hires get 16,650 options plus RSUs - Stock Titan
Bear Alert: How does Arcus Biosciences Inc score in quality rankingsJuly 2025 Analyst Calls & Community Consensus Trade Alerts - baoquankhu1.vn
Responsive Playbooks and the RCUS Inflection - Stock Traders Daily
Market Review: Can Arcus Biosciences Inc be recession proofWeekly Risk Summary & Breakout Confirmation Trade Signals - baoquankhu1.vn
Published on: 2026-01-23 23:49:02 - baoquankhu1.vn
EPS Watch: How correlated is Arcus Biosciences Inc to the S P5002025 Analyst Calls & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Will Arcus Biosciences Inc. stock recover faster than marketPortfolio Risk Assessment & Free Daily Top Stock Picks for All Investors - bollywoodhelpline.com
Arcus Biosciences, Inc. (NYSE:RCUS) Sees Significant Increase in Short Interest - MarketBeat
Arcus Biosciences (NYSE:RCUS) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Arcus Biosciences appoints new Chief Medical Officer - MSN
Arcus Biosciences (NYSE:RCUS) Trading Down 5.8%Time to Sell? - MarketBeat
Is Arcus Biosciences (RCUS) Using Casdatifan to Quietly Redefine Its Core Oncology Strategy? - Sahm
Goldman Sachs Upgrades Arcus Biosciences (RCUS) to 'Buy', Raises Price Target | RCUS Stock News - GuruFocus
Goldman Sachs Upgrades Arcus Biosciences (RCUS) - Nasdaq
Understanding the Setup: (RCUS) and Scalable Risk - Stock Traders Daily
Arcus Biosciences stock jumps on Goldman upgrade as traders eye JPM Healthcare stage - TechStock²
Arcus Biosciences (NYSE:RCUS) Shares Gap UpHere's What Happened - MarketBeat
Goldman Sachs resumes Arcus Biosciences stock coverage with Buy rating By Investing.com - Investing.com South Africa
Goldman Sachs resumes Arcus Biosciences stock coverage with Buy rating - Investing.com India
Risk Check: What is Arcus Biosciences Incs valuation compared to sectorJuly 2025 Big Picture & High Accuracy Investment Signals - baoquankhu1.vn
Arcus downgraded at Morgan Stanley on balanced risk-reward setup - MSN
Arcus Biosciences (RCUS) Valuation Check After Recent Share Price Pullback And 1 Year Gain - Yahoo Finance
Los Angeles Daily NewsArcus Biosciences, Inc. Common Stock (NYSE:RCUS) Stock Quote - FinancialContent
Wall Street Zen Downgrades Arcus Biosciences (NYSE:RCUS) to Sell - MarketBeat
Can Arcus Biosciences Inc. stock double in next 5 yearsMarket Performance Recap & AI Enhanced Trade Execution Alerts - Улправда
Arcus Biosciences (RCUS) CEO Terry Rosen donates 35,000 shares in Form 4 - Stock Titan
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Will Arcus Biosciences Inc. stock continue upward momentumWatch List & AI Optimized Trade Strategies - ulpravda.ru
Is Arcus Biosciences Inc. stock a buy for dividend growthWeekly Market Outlook & Smart Allocation Stock Tips - Улправда
Growth Review: Is Arcus Biosciences Inc. stock a buy for dividend growth2025 Trading Volume Trends & Fast Moving Stock Trade Plans - Улправда
Arcus Biosciences (RCUS) Downgraded by Morgan Stanley Amid Recen - GuruFocus
Is Arcus Biosciences Inc. stock attractive after correctionMarket Sentiment Report & Precise Trade Entry Recommendations - ulpravda.ru
Arcus Biosciences (NYSE:RCUS) stock slides on Morgan Stanley downgrade as casdatifan 2026 timeline sharpens - TechStock²
BlackRock (RCUS) Schedule 13G/A shows 12.7M Arcus Biosciences shares owned - Stock Titan
Will Arcus Biosciences Inc. stock maintain growth storyJuly 2025 Earnings & Accurate Buy Signal Alerts - Улправда
Arcus stock downgraded at Morgan Stanley (RCUS:NYSE) - Seeking Alpha
Arcus Biosciences (NYSE:RCUS) Shares Gap Down on Insider Selling - MarketBeat
Morgan Stanley Downgrades Arcus Biosciences (RCUS), Adjusts Pric - GuruFocus
Morgan Stanley downgrades Arcus Biosciences stock on balanced risk/reward - Investing.com Canada
Insider Selling: Arcus Biosciences (NYSE:RCUS) President Sells 31,823 Shares of Stock - MarketBeat
Arcus Biosciences (RCUS) Sets Ambitious 2026 Agenda for Casdatif - GuruFocus
Biotech outlines 2026 plans for kidney cancer and atopic dermatitis - Stock Titan
Arcus Biosciences President Sells $2 Million as Stock Delivers 48% Annual Return - Yahoo Finance
RCUS (NYSE: RCUS) trust files Rule 144 to sell 31,823 Class A shares - Stock Titan
RCUS SEC FilingsArcus Bioscience 10-K, 10-Q, 8-K Forms - Stock Titan
Arcus Biosciences (RCUS) Shares Fall by Over 9% - GuruFocus
Arcus Biosciences (NYSE:RCUS) Trading Down 7.8% Following Insider Selling - MarketBeat
Portfolio Shifts: Is Arcus Biosciences Inc stock a buy for dividend growthLong Setup & AI Powered Buy and Sell Recommendations - Bộ Nội Vụ
Insider Sell: Goeltz II Robert C. Sells Shares of Arcus Bioscien - GuruFocus
Arcus Biosciences Inc Stock (RCUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.09%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):